At Dynavax’s third try, an FDA panel favored hepatitis B candidate Heplisav-B's safety profile by a vote of 12 to 1.

J&J's Janssen unit will shell out up to $879 million to develop HIV and HBV vaccines using Bavarian Nordic's MVA-BN technology.

On the heels of new genital herpes data, one analyst believes things may get a whole lot better at Genocea.

Novavax's shares slid 19% after topline data from a new phase 2 trial on its RSV vaccine fail to impress investors.

With early HIV vaccine results announced Monday, Johnson & Johnson and its partners hope they might have a winner.

U.S. Merck's shingles vaccine Zostavax faces a growing challenge in court.

It's summer, when few are thinking about the coming influenza threat. But top vaccine makers are already kicking off their flu shot shipments.

VBI Vaccines hopes to challenge the hepatitis B vaccine standard-of-care, a position long held by GlaxoSmithKline’s Engerix-B.